205 related articles for article (PubMed ID: 22348073)
21. Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells.
Nieto-Miguel T; Gajate C; Mollinedo F
J Biol Chem; 2006 May; 281(21):14833-40. PubMed ID: 16540473
[TBL] [Abstract][Full Text] [Related]
22. Effects of the ether phospholipid AMG-PC on mast cells are similar to that of the ether lipid AMG but different from that of the analogue hexadecylphosphocholine.
Grosman N
Immunopharmacology; 1991; 22(1):39-47. PubMed ID: 1791141
[TBL] [Abstract][Full Text] [Related]
23. Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids.
Castro BM; Fedorov A; Hornillos V; Delgado J; Acuña AU; Mollinedo F; Prieto M
J Phys Chem B; 2013 Jul; 117(26):7929-40. PubMed ID: 23738749
[TBL] [Abstract][Full Text] [Related]
24. Biosynthesis and biotransformation of ether lipids.
Mangold HK; Weber N
Lipids; 1987 Nov; 22(11):789-99. PubMed ID: 3328026
[TBL] [Abstract][Full Text] [Related]
25. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells.
van der Luit AH; Vink SR; Klarenbeek JB; Perrissoud D; Solary E; Verheij M; van Blitterswijk WJ
Mol Cancer Ther; 2007 Aug; 6(8):2337-45. PubMed ID: 17699729
[TBL] [Abstract][Full Text] [Related]
26. The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway.
Lim SC; Parajuli KR; Han SI
Tumour Biol; 2016 May; 37(5):6205-16. PubMed ID: 26615420
[TBL] [Abstract][Full Text] [Related]
27. Conserved Functions of Ether Lipids and Sphingolipids in the Early Secretory Pathway.
Jiménez-Rojo N; Leonetti MD; Zoni V; Colom A; Feng S; Iyengar NR; Matile S; Roux A; Vanni S; Weissman JS; Riezman H
Curr Biol; 2020 Oct; 30(19):3775-3787.e7. PubMed ID: 32857977
[TBL] [Abstract][Full Text] [Related]
28. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents.
Wagner BA; Buettner GR; Burns CP
Cancer Res; 1992 Nov; 52(21):6045-51. PubMed ID: 1394229
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.
Varela-M RE; Villa-Pulgarin JA; Yepes E; Müller I; Modolell M; Muñoz DL; Robledo SM; Muskus CE; López-Abán J; Muro A; Vélez ID; Mollinedo F
PLoS Negl Trop Dis; 2012; 6(4):e1612. PubMed ID: 22506086
[TBL] [Abstract][Full Text] [Related]
30. Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells.
Gajate C; Santos-Beneit AM; Macho A; Lazaro Md; Hernandez-De Rojas A; Modolell M; Muñoz E; Mollinedo F
Int J Cancer; 2000 Apr; 86(2):208-18. PubMed ID: 10738248
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial Targeting Involving Cholesterol-Rich Lipid Rafts in the Mechanism of Action of the Antitumor Ether Lipid and Alkylphospholipid Analog Edelfosine.
Mollinedo F; Gajate C
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34065546
[TBL] [Abstract][Full Text] [Related]
32. IDENTIFICATION OF ALPHA-GLYCERYL ETHER PHOSPHOLIPIDS AS MAJOR LIPID CONSTITUENTS IN TWO SPECIES OF TERRESTRIAL SLUG.
THOMPSON GA; HANAHAN DJ
J Biol Chem; 1963 Aug; 238():2628-31. PubMed ID: 14063283
[No Abstract] [Full Text] [Related]
33. Ether lipids and analogs in experimental cancer therapy. A brief review of the Munich experience.
Berdel WE
Lipids; 1987 Nov; 22(11):970-3. PubMed ID: 3328030
[TBL] [Abstract][Full Text] [Related]
34. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis.
Gajate C; Fonteriz RI; Cabaner C; Alvarez-Noves G; Alvarez-Rodriguez Y; Modolell M; Mollinedo F
Int J Cancer; 2000 Mar; 85(5):674-82. PubMed ID: 10699948
[TBL] [Abstract][Full Text] [Related]
35. Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy.
Jaffrès PA; Gajate C; Bouchet AM; Couthon-Gourvès H; Chantôme A; Potier-Cartereau M; Besson P; Bougnoux P; Mollinedo F; Vandier C
Pharmacol Ther; 2016 Sep; 165():114-31. PubMed ID: 27288726
[TBL] [Abstract][Full Text] [Related]
36. Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440.
Petersen ES; Kelley EE; Modest EJ; Burns CP
Cancer Res; 1992 Nov; 52(22):6263-9. PubMed ID: 1423272
[TBL] [Abstract][Full Text] [Related]
37. Edelfosine and perifosine disrupt hepatic mitochondrial oxidative phosphorylation and induce the permeability transition.
Burgeiro A; Pereira CV; Carvalho FS; Pereira GC; Mollinedo F; Oliveira PJ
Mitochondrion; 2013 Jan; 13(1):25-35. PubMed ID: 23164800
[TBL] [Abstract][Full Text] [Related]
38. Increased ether lipid cytotoxicity by reducing membrane cholesterol content.
Diomede L; Piovani B; Modest EJ; Noseda A; Salmona M
Int J Cancer; 1991 Sep; 49(3):409-13. PubMed ID: 1917140
[TBL] [Abstract][Full Text] [Related]
39. ERK1/2 acts as a switch between necrotic and apoptotic cell death in ether phospholipid edelfosine-treated glioblastoma cells.
Melo-Lima S; Lopes MC; Mollinedo F
Pharmacol Res; 2015; 95-96():2-11. PubMed ID: 25749008
[TBL] [Abstract][Full Text] [Related]
40. The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-OMe.
Lohmeyer M; Workman P
Biochem Pharmacol; 1993 Jan; 45(1):77-86. PubMed ID: 8424826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
